Genetics of QT Prolongation With Antiarrhythmics

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being loaded with dofetilide or sotalol.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborators: Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Mayo Clinic; The Cleveland Clinic; University of Colorado, Denver; VA Office of Research and Development
• Treatments: Anti-Arrhythmia Agents; Dofetilide; Sotalol

Criteria

Inclusion Criteria:

• All patients admitted for dovetailed or sotalol initiation for clinical purposes.

Exclusion Criteria:

• Inability to provide informed consent

• Inability to provide blood samples for DNA testing (anemia, coagulopathy)